SCHEMBL19504480

SCHEMBL19504480

COC1CN(C(=O)C2CCN(C(C)(C)C)CC2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RECQL P46063 1/20 0.39
ATM Q13315 1/20 0.38
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
CHRNB2 P17787 5/20 0.36
CHRNA3 P32297 5/20 0.36
CHRNA4 P43681 5/20 0.36
CHRNB3 Q05901 4/20 0.36
CHRNA6 Q15825 4/20 0.36
HSD11B1 P28845 3/20 0.36
ALDH1A1 P00352 2/20 0.35
TSHR P16473 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA7 P36544 1/20 0.35
HSD11B2 P80365 1/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27022736 0.87 HPGD (0.38) HPGDSMN1; SMN2RECQLATMNPC1
SCHEMBL24707744 0.82 CHRNB2 (0.50) HPGDSMN1; SMN2CHRNB2CHRNA3CHRNA4
SCHEMBL19498126 0.81 GRM5 (0.36) HPGDSMN1; SMN2ATMNPC1RAB9A
SCHEMBL25143661 0.79 ALDH1A1 (0.52) HPGDSMN1; SMN2RECQLHRH3CHRNB2
SCHEMBL27022710 0.79 HPGD (0.42) HPGDSMN1; SMN2RECQLHRH3CHRNB2
SCHEMBL10205143 0.78 HPGD (0.55) HPGDSMN1; SMN2RECQLNPC1RAB9A
SCHEMBL20746951 0.78 HPGD (0.61) HPGDSMN1; SMN2RECQLATMNPC1
SCHEMBL18051840 0.78 HSD11B1 (0.60) SMN1; SMN2NPC1RAB9AKMT2ACHRNB2
SCHEMBL23776750 0.77 HRH3 (0.56) HPGDSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL21569674 0.77 HSD11B1 (0.43) HPGDSMN1; SMN2RECQLHRH3CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305922-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305922-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, ADRM1, PRMT1 HPGD 4411/4885SMN1; SMN2 1375/4885RECQL 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.